Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United ...

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone.

The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...